NEW YORK – Prostate cancer is a burgeoning disease market, but a recent spate of promising clinical news from the drug development industry is also offering optimism for the potential for an equally growing market for drug approvals to address the disease.

NEW YORK – Scores of industry senior executives and the professionals who finance and invest in their drug development pursuits have descended upon New York – which is still in the throes of a most frigid winter – to attend the 13th annual Biotechnology International Organization (BIO) CEO & Investor Conference taking place Monday and Tuesday at the Waldorf-Astoria Hotel. They have come to address the cold-reality financial and investment landscape issues affecting continued post-recession growth in the biotechnology market.